Introduction
Methods
Information sources
Eligibility criteria
Data extraction
Missing data
Calculated data variables
Infected and deceased community-dwelling elderly
IFR estimation
Synthesis of data
Ethics approval
Patient and public involvement
Results
Seroprevalence studies
Location (first author) | Recruitment strategy | Sampling period | Number tested; number positive (n) | Age cutoff for mortality; age cutoff for seroprevalence (years) | Antibody type(s) | Adjusted seroprevalence; crude seroprevalence (%) | Adjustments | Deaths in community-dwelling elderly [all elderly] (n) | Population, community-dwelling elderly [all elderly] (n) | IFR community-dwelling elderly [all elderly] (%) |
---|---|---|---|---|---|---|---|---|---|---|
Main analysis | ||||||||||
Andorra (Royo-Cebrecos)* | General | May 4 to May 28 | 4339; 582 | 70; 70 | IgG/IgM | NA; 14.92 | None | 22 [45] | 7364 [7631] | 2.02 [3.95] |
Ontario, Canada (Public Health Ontario, COVID-19 Immunity Task Force) | General | June 5 to June 30 | 1236; 25 | 70; 70 | IgG | 1.92; 2.02 | Population weighting and test characteristics | 525 [2298] | 1,392,596 [1513920] | 1.96 [7.89] |
Denmark (Espenhain) | General | Median date Sept 19, sampling period approx. 13 weeks | 1473; NA | 70; 65 | IgG/IgM/IgA | 1.5; NA | Test sensitivity and specificity | 350 [565] | 798,797 [836716] | 2.92 [4.5] |
France (Warszawski, INSERM)* | General | Median date Nov 24, interquartile range Nov 18 to Dec 4 | 14,531; 611 | 65; 65 | IgG | 5.05; 5.27 | Sociodemographics, income, quality of contact information, population density, proportion of people below poverty line, age, gender, "departement", educational level, region | 26,958 [49488] | 12,902,526 [13440786] | 4.14 [7.29] |
Ile-de-France, France (Carrat) | General | May 4 to June 23 (90% of tests were performed May 4 to May 24) | 1394; 52 | 70; 70 | IgG | 4.73; 3.73 | Age, sex, socio-professional category, test sensitivity and specificity | 4297 [7712] | 1,279,740 [1339192] | 7.1 [12.18] |
Nouvelle-Aquitaine, France (Carrat) | General | May 4 to June 23 (90% of tests were performed May 4 to May 24) | 1765; 29 | 65; 65 | IgG | 1.7; 1.64 | Age, sex, socio-professional category, test sensitivity and specificity | 303 [409] | 1,406,958 [1465885] | 1.27 [1.65] |
Hungary (Merkely)* | General | May 1 to May 16 | 1454; 9 | 70; 70 | IgG | 1.12; 0.93 | "several area-, dwelling unit-, and individual-level auxiliary information", region, sex, age | 248 [348] | 1,198,425 [1249016] | 1.85 [2.48] |
Iceland (Gudbjartsson) | General | May 5 to June 12 (healthcare sample) | NA; NA | 70; 70 | IgG/IgM/IgA | 0.47; NA | Region, sex, age | 5 [7] | 32,782 [34865] | 3.12 [4.23] |
Italy (ISTAT) | General | May 25 to July 15 | NA; NA | 70; 70 | IgG | 2.5; NA | Region, municipal type, gender, age group, employment status, municipal prevalence, percentage difference in municipal mortality rates compared to the same period of the previous year | 19,341 [29722] | 10,136,405 [10400756] | 7.63 [11.43] |
Netherlands (Vos) | General | June 9 to August 24; 90% enrolled by June 22 | 788; NA | 70; 70 | IgG | 5; NA | Sex, age, ethnic background, degree of urbanization, test characteristics | 2664 [5402] | 2,346,712 [2451000] | 2.27 [4.41] |
Spain (ISCII)* | General | November 16 to November 29 | 7526; NA | 70; 70 | IgG | 7.88; NA | Province, sex, age, income | 23,335 [41681] | 6,512,456 [6823002] | 4.55 [7.75] |
England (Ward) | General | June 20 to July 13 | 21,953; 801 | 70; 65 | IgG | 3.25; 3.65 | Test performance, age, sex, region, ethnicity, deprivation | 22,644 [41023] | 7,204,057 [7556976] | 9.68 [16.72] |
USA (Kalish) | General | April 1 to August 2020 (> 88% between May 10 and July 31) | 1273; 46 | 65; 70 | IgG/IgM/IgA | 3.5; 3.61 | Region, age, sex, race, ethnicity, urban/rural, children, education, homeowner, employment, health insurance, health-related questions, test performance | 46,571 [103862] | 52,441,191 [54058263] | 2.27 [4.42] |
Sensitivity analysis (Non-peer-reviewed pre-specified selection criteria) | ||||||||||
Belgium (Herzog) | Residual blood samples | Mar 30 to Apr 5 | 1210; 29 | 70; 70 | IgG | 1.92; 2.4 | Age, sex, province, test sensitivity and specificity | 1057 [3317] | 1,453,077 [1581078] | 3.79 [10.92] |
Canada (Saeed, Canadian Blood Services) | Blood donors | May 9 to July 21 (median date June 13) | 9845; 74 | 70; 65 | IgG | 0.77; 0.75 | Residential postal code, age, sex, sensitivity and specificity of the assay | 890 [7477] | 3,577,421 [3963155] | 3.23 [24.5] |
Alberta, Canada (Charlton)* | Residual blood samples | December 7 to December 10 | 2820; 29 | 70; 70 | IgG | 1.54; 1.54 | None (crude) | 213 [823] | 289,046 [326530] | 4.8 [16.41] |
Denmark (Pedersen) | Blood donors | June 2 to June 19 | 1201; 22 | 70; 70 | IgG/IgM/IgA | 1.4; 1.8 | Sensitivity and specificity of the diagnostic assay; population size of recruitment areas (municipalities) | 329 [531] | 530,764 [555882] | 4.43 [6.82] |
Dominican Republic (Paulino-Ramirez)* | General, hotspot areas | April to June | 2739; 164 | 60; 60 | IgG | NA; 10.53 | None | 237 [282] | 1,156,871 [1158933] | 0.19 [0.23] |
India (Murhekar) | General | August 19 to September 20 | 2768; 291 | 61; 61 | IgG | 6.2; 10.51 | Sampling district, test performance | 33,655 [41386] | 125,239,515 [125325806] | 0.43 [0.53] |
Tamil Nadu, India (Malani) | General | October 19 to November 30 | 1568; NA | 70; 70 | IgG | 25.2; NA | Age, gender, test performance, district | 3518 [4326] | 4,324,265 [4328822] | 0.32 [0.4] |
Israel (Reicher)* | General | Median date July 9 | 6937; NA | 70; 70 | IgG | 2.22; NA | Sex, age, municipal strata and RT-PCR status | 163 [327] | 652,486 [689587] | 1.12 [2.14] |
Qatar (Abu-Raddad)* | Residual blood samples | May 12 to July 12 (median day June 28) | 1809; 162 | 70; 70 | IgG | 13.29; 9.15 | Sex, age, nationality | 53 [65] | 18,166 [18247] | 2.18 [2.67] |
UK (UK Biobank) | Biobank | May 27 to Aug 14 (however monthly repeated sampling) | 3956; NA | 65; 70 | Missing/Unclear | 6.1; NA | Unclear | 25,678 [49669] | 11,917,570 [12374961] | 3.53 [6.58] |
England and Wales (Public Health England) | Residual blood samples | May 1 to May 30 | 1702; NA | 70; 70 | Missing/Unclear | 3.64; NA | Population-weighted adjusted | 21,063 [37838] | 7,665,426 [8037210] | 7.55 [12.94] |
Greater Glasgow and Clyde, Scotland (Hughes) | Residual blood samples | March 16 to May 24 | 2771; NA | 70; 65 | IgG | 5.45; 8.23 | Test performance, population-level dynamics, sex, age, care type, week of sample collection | 295 [627] | 188,673 [195952] | 2.87 [5.87] |
USA (Anand)* | Hemodialysis | July (> 80% in first 2 weeks) | 13,659; 1043 | 65; 65 | IgG/IgM/IgA | 8.09; 7.65 | Age, sex, geographical region, race and ethnicity | 51,128 [111774] | 52,441,191 [54058263] | 1.2 [2.55] |